A randomized phase 2 study of the thrombospondin-mimetic peptide ABT-510 in patients with previously untreated advanced renal cell carcinoma
Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), Robert A. Figlin(Palmetto Hematology Oncology), Nizar M. Tannir(The University of Texas MD Anderson Cancer Center), Michael S. Gordon(Pinnacle Oncology Hematology), Dawn M. Carlson(University of Arizona), M Hussain(University of Arizona), Anjali Desai(University of Arizona), Raymond A. Knight(Bridgewater State University)
Cited by 9
Related Papers
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k